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Chapter 1 
Introduction 
 
1.1 Cancer 
Cancer is a type of disease defined by abnormal growth of cells called tumor resulting from 
the accumulation of gene mutations with two heritable properties; uncontrolled proliferation and 
colonization into other tissues. Tumors can be classified as benign or malignant. Benign tumors 
grow locally and remain clustered together, thus considered noncancerous, while malignant 
tumors have the ability of invading neighboring tissues, entering blood vessels and lymph system 
and metastasize to different sites. The progression of cancer can be explained by three key steps 
involving (a) initiation, in which normal cell is converted into initiated or abnormal cell, (b) 
promotion, the process of which the initiated cells is transformed into a pre-malignant cells, and 
(c) progression, by which  the cells become neoplastic or malignant [1].  
1.2 Pancreatic Cancer 
Pancreatic cancer is a condition in which malignant cells are found in pancreatic tissues. 
The pancreas is a 6-inch organ located behind the stomach made up of both exocrine and 
endocrine glands. The exocrine cells of the pancreas secrete digestive enzymes which are being 
released into a system of small ducts that lead to the main pancreatic duct. In the digestive 
system, both pancreatic duct and bile duct connect together where pancreatic juice and bile will 
be emptied into the duodenum, aiding in the digestion of fats, proteins and carbohydrates. On the 
other hand, the endocrine cells of the pancreas are involved in the production of hormones, 
mainly insulin and glucagon. These hormones are secreted by islet cells into the bloodstream, 
working together in maintaining the normal level of blood glucose in the body. 
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Pancreatic cancer is  currently ranked as the fourth leading cause of cancer-related deaths 
in the United States with 95% of the cases emerging from the exocrine cells, the most common 
type being the  pancreatic ductal adenocarcinoma (PDAC), while the remaining 5% develop 
from the endocrine cells [2].  Although accounting for the least percentage of incidences among 
other types of digestive system cancers, pancreatic cancer still remains as one of the most lethal 
types of malignancies with the five year survival rate of less than five percent. The American 
Cancer Society estimated that in 2013, 45220 of new cases of pancreatic cancer would be 
diagnosed  and 85%  of death  from this number is expected due to this disease [3]. Late 
diagnosis, early metastasis of tumors and poor response to treatments contribute to the high 
mortality rate [4]. 
It is now widely accepted that the cause for pancreatic cancer is related to the 
accumulation of genetic mutations and alterations which results in oncogenes being highly 
expressed, inactivation of tumor suppressor genes and overexpression of growth factors and their 
receptors [5, 6].  
In pancreatic cancer, K-ras mutations are the most commonly seen oncogene mutations 
which appear in more than 95% of pancreatic cancer tissues. The normal K-ras proto-oncogene 
encodes a guanine nucleotide-binding protein which plays role in cell growth and differentiation 
[7, 8]. The activated K-ras oncogene by means of point mutations in either codon 12, 13 or 61 
has an abnormal increase in membrane-bound ras proteins which appears to induce tumor 
development by altering the signal transduction pathway across the membrane leading to an 
abnormal, uncontrolled cell growth [8]. It is believed that mutations of K-Ras take place in the 
early stage of pancreatic carcinogenesis [6]. 
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P53 is a tumor suppressor gene located on the short arm of chromosome 17 that encodes 
a 53kDa nuclear phosphoprotein which plays role in the negative regulation of cell growth and 
proliferation. It is an important  tumor suppressor genes inactivated in pancreatic cancer [9].  P53 
mutations have been found to occur in 40% to 70% of pancreatic adenocarcinoma cases and its 
contribution to tumorigenesis is suggested to be through the inhibition of apoptosis [10]. In 
contrast to K-Ras oncogene, whether p53 abnormalities are an early or late event in pancreatic 
cancer is inconclusive [6].  
Growth factors and their receptors pose meaningful functions in the progression of tumor 
[11]. Over expression of growth factors such as EGF, TGF alpha, TGF beta 1-3, growth factor 
receptors including EGF receptor, c-erbB-2, c-c-ebB-3, TGF beta receptor I-III together with 
genetic mutations mainly K-ras, p53 are of significant existance in a number of gastrointestinal 
cancers [12]. These abnormalities stimulate tumor growth and exaggerate the metastatic behavior 
of pancreatic cancer cells to such a degree that may contribute to poor prognosis following 
treatments of this disease [6]. The mouse model selected for the study has mutations in K-ras and 
p53 genes, leading to pancreatic cancer manifestation, similar to human. 
1.2.1 Clinical presentation and diagnosis 
Symptoms presented by pancreatic cancer are not exclusive to the disease and differ 
depending on the location of tumor as well as the stage of the disease. Although the etiology of 
pancreatic cancer remains unknown, several risk factors have been suggested such as male 
gender, black race, meat and fat consumption, cigarette smoking, pancreatic ductal hyperplasia 
and chronic pancreatitis. Since the majority of tumors develop in the head of the pancreas, 
obstructive cholestasis is normally manifested. Rarely, a pancreatic tumor may also cause 
gastrointestinal bleeding or duodenal obstruction while obstruction of the pancreatic duct by 
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tumor may lead to pancreatitis. Pancreatic cancer generally causes abdominal discomfort, nausea 
and dull, deep upper abdominal pain. For most patients, systemic manifestations of this disease 
include anorexia, weight loss and asthenia. Other less common manifestations include deep and 
superficial venous thrombosis, increased abdominal girth, panniculitis, gastric-outlet obstruction 
and depression. Upon physical examination, jaundice, temporal wasting, hepatomegaly and 
ascites may be observed. Patients may also have mild liver-function test abnormalities, 
hyperglycemia and anemia [2, 13, 14]. 
Commonly, contrast-enhanced computerized tomography (CT) is sufficient to help in the 
diagnosis of pancreatic cancer. Other imaging tests use to diagnose this disease include 
ultrasound and magnetic resonance imaging (MRI). Some other diagnostic tools that is also 
useful are endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography 
(ERCP). In terms of serum biomarker, CA 19-9 is the only biomarker that has demonstrated 
clinical usefulness for therapeutic monitoring and early detection of recurrent event of pancreatic 
cancer despite its limitation of not being a solely specific biomarker for this disease [15, 16]. CA 
19-9 may also be elevated in other malignancies such as lung cancer, colorectal cancer and 
cancer of the gall bladder as well as in non-cancerous conditions such as gall stones, pancreatitis, 
liver disease and cystic fibrosis. In our study, tumor development and progression in live animals 
was monitored by MRI. 
1.2.2 Pancreatic cancer staging  
According to the most recent edition of the American Joint Committee on Cancer, 
pancreatic cancer is staged based on tumor-node-metastasis classification. Staging of pancreatic 
cancer comprised of five stages namely stage 0, stage I, stage II, stage III and stage IV together 
with tumor grade, nodal status and distant metastases. In stage 0, abnormal cells are found in the 
5 
 
lining of the pancreas. These abnormal cells may become cancer and spread into nearby 
normal tissue. Stage 0 is also called carcinoma in situ, an early form of cancer defined by 
abnormal cells are still within the site of origin with the absence of spreading or invasion to 
nearby tissues. In stage I, cancer has formed and is found in the pancreas only. Based on the size 
of the tumor, stage I is divided into stage IA (tumor size of 2 centimeters or smaller) and stage IB 
(tumor size larger than 2 centimeters). In stage II, cancer may have spread to 
nearby tissue and organs, and may have spread to lymph nodes near the pancreas. Stage II is 
further divided into stage IIA where cancer has spread to nearby tissue and organs but has not 
spread to nearby lymph nodes and stage IIB where cancer has spread to nearby lymph nodes and 
may have spread to nearby tissue and organs. As pancreatic cancer advances into stage 
III, cancer has now spread to the major blood vessels near the pancreas including the superior 
mesenteric artery, celiac axis, common hepatic artery, and portal vein, and may have also spread 
to nearby lymph nodes. In the final stage of pancreatic cancer, stage IV, cancer may be of any 
size and has metastasize to distant organs, such as the liver, lung, and peritoneal cavity. It may 
have also spread to organs and tissues near the pancreas or to lymph nodes [17]. 
In PDAC, the growth of pancreatic cancer arises from the ductal epithelium and 
progresses from pre-malignant lesion to fully invasive cancer [2]. The progression of this disease 
can also be graded by looking at the changes that happen to lesion called pancreatic 
intraepithelial neoplasia (panIN). PanINs are proliferations of the smaller pancreatic ducts that 
can be viewed microscopically. Classification of PanIN represent step by step morphological 
alterations that happen in the pancreatic ductal epithelium. A normal pancreatic duct is 
characterized by low cuboidal, non-mucinuous cells in a single layer formation.  Low-grade 
PanINs (PanIN-1a and PanIN-1b) are characterized by the change from a cuboidal duct 
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epithelium to elongated cells and by the abundant accumulation of mucin. PanIN-1a lesion is 
made up of columnar shape cells with the presence of mucin production. PanIN-1b lesion is 
somewhat identical to PanIN-1a except for its architectural difference. PanIN-1b has a papillary, 
micropapillary or basally pseudostratified architecture. As the lesions advance from PanIN-1 to 
PanIN-2, some nuclear abnormalities have emerged which can be viewed under a microscope. 
The architectural make up of mucinuos epithelial lesion of  PanIN-2 can either be flat or 
papillary. Some of the nuclear alterations that can be seen in PanIN-2 lesion include loss of 
polarity, nuclear crowding, enlarged nuclei, pseudo-stratification and hyperchromatism. PanIN-3 
lesion is a pre-invasive form of adenocarcinoma (carcinoma in situ). It is architecturally 
 papillary or micropapillary, however, they may also appeared flat. This lesion may form 
budding into the pancreatic lumen with the observance of severe nuclear atypia and some 
abnormal mitosis [18].  In the overall study, the PanIN system was used to confirm the presence 
of cancer in the pancreas and liver tissue by histological methods. 
1.2.3 Treatment and prognosis 
Treatment plan for pancreatic cancer depends on the possibility of performing complete 
surgery to remove the cancer.  Surgery is the only potential treatment to cure the disease. 
Unfortunately this option is only limited to patients diagnosed with early stage of pancreatic 
cancer, mainly stage I and some of stage II cases [19, 20]. Only 20% of cases can be surgically 
removed at the time of diagnosis while in the remaining 80% of cases, the tumor is unresectable 
or curative treatment by surgical techniques alone is less beneficial [20]. The most common 
operative procedures involve cephalic pancreatoduodenectomy (the Whipple procedure); when 
the tumor is in the head or uncinate process, distal subtotal pancreatectomy; when the tumor is 
located the body or tail of the pancreas and in some cases may involve total pancreatectomy. 
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Observations from several randomized clinical trials demonstrate that a more extensive surgical 
resection does not improve survival due to the increase risk of postoperative morbidity [2]. This 
poor prognosis is contributed by several factors including large tumor size, high tumor grade, 
lymph-node metastases and high level of CA 19-9 that continue to elevate persistently in 
postoperative setting [21, 22].  
 Despite being the only possible curative treatment for pancreatic cancer, prognosis 
following total resection of tumor alone in early-stage patients is somewhat disappointing [2]. 
Data from several studies have shown that adjuvant therapy through postoperative administration 
of chemotherapy with either leucovorin  and fluorouracil or gemcitabine improves overall 
survival [23-25]. In addition, the combination of gemcitabine with fluorouracil given as 
continuous infusion and radiation therapy has also shown an increase in overall survival with a 
median survival of 20 to 22 months [2, 26] .  Hence, the use of gemcitabine alone or gemcitabine 
in combination with fluruouracil-based chemoradiation postoperatively can be acknowledged as 
the standard of care for the management of early-stage pancreatic cancer. Interestingly, the 
emerging use of preoperative (neoadjuvant) gemcitabine-based chemoradiation treatment has 
also been demonstrated to be at least as effective as postoperative (adjuvant) treatment in patients 
with resectable pancreatic cancer [27]. 
As the disease progresses to becoming locally and systemically advanced, tumor is no 
longer resectable. In these cases, treatment is palliative with median overall survival ranges from 
9 to 10 months. Treatment options diverge from chemotherapy alone to combination of treatment 
with chemoradiation therapy and chemotherapy. Data from several randomized trials has 
established that chemoradiation therapy is better than radiation therapy alone [28, 29]. 
Gemcitabine, a genotoxic drug has been the treatment of choice for pancreatic cancer particularly 
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for patients with nonresectable pancreatic cancer.  It is the current standard therapy that is known 
to extend survival by a matter of weeks [30]. Several new agents have been tested in 
combination with gemcitabine in clinical trials but with no betterment in outcome [13, 31, 32]. 
The only agent, used in combination with gemcitabine that has shown a small yet significant 
increase in survival among patients diagnosed with advanced pancreatic cancer is erlotinib 
though this combination has more toxicity when compared with erlotinib alone [33]. To date, the 
treatment approach  in acceptance for patients with advanced pancreatic cancer is either 
gemcitabine administration alone or gemcitabine in combination with a platinum agent, erlotinib, 
or a fluropyrimidine [32, 33]. 
Newer approach through the use of phytochemicals, the naturally occurring, plant-based 
substances is of the current  research interest in the hope to combat pancreatic cancer. Garcinol, a 
bioactive agent from plant is one of the phytochemicals that has drawn researchers’ attention for 
its anticancer properties, both as therapeutics and chemoprevention.  
1.3 Garcinol 
Garcinol is a yellow crystalline polyisoprenylated benzophenone derivative, extracted 
from Garcinia indica fruit rind.  Also popularly known as Kokum or Mangosteen, it can be 
largely found in tropical regions of Asia and Africa. Characterized by its sweet and sour taste, 
this fruit has long been incorporated in cooking, enjoyed as snack and served as a refreshing 
drink. It is also traditionally used in the treatment of some illnesses such as heat strokes and 
infections [34]. 
  The chemical structure of Garcinol (C38H50O6; molecular weight 602), also called 
Camboginol (Figure 1) was defined using NMR and IR spectroscopy back in 1980 by Rao and 
coworkers [35]. It shares a structure similar with curcumin, a compound known to possess 
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antioxidant, antiaging and anticarcinogenic properties by means of containing both phenolic 
hydroxyl groups and the ß-diketone moiety [35]. Some other known properties of garcinol 
include antiulcer, antitumorigenic, antiobesity, anti-inflammatory, antibacterial and antiviral 
which associated with its isomer isogarcinol [36]. 
1.3.1 Anticancer Properties of Garcinol  
The potential of garcinol as chemopreventative and therapeutic agent for different types 
of cancer have been reported by a number of studies conducted recently. The mechanistic targets 
of the anticancer activity of Garcinol is depicted as Figure 2 [37]. 
 
 
 
Fig. 1 Chemical structure of garcinol [38] 
 
Its effect on oxidative and inflammatory pathways has been investigated both in vitro and 
in vivo. A colon cancer study on F344 rats conducted in Tanaka lab showed a significant 
reduction in a dose-dependent manner on the formation of colon cancer precursors known as 
azoxymethane-(AOM)-induced colonic aberrant crypt foci (ACF) following of 0.01% and 0.05% 
dietary garcinol intervention. Garcinol has also been noted to inhibit O2-, iNOS, Nitric Oxide 
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(NO) and COX2 and interestingly found to act more potently than the green tea polyphenol, 
epigallocatechin gallate (EGCG) in the cell lines studied [38]. In another in vivo study, ingestion 
of dietary garcinol by rats exposed with 4-nitroquinoline 1-oxide (4-NQO) to induce tongue 
lesions has also shown to lower the expression of COX2 as compared to control diet [39]. 
Similar effect of inflammatory response was also observed in macrophage cell lines, by which 
the expression of both NF-ĸB and COX2 have been down-regulated following garcinol treatment 
[40]. 
 
 
 
Fig. 2 Mechanistic targets of garcinol anticancer activity [37] 
 
Apart from that, garcinol has also been documented as being potent in halting cancerous 
growth by targeting apoptosis, programmed cell death of cancer cells. In a human leukemia cell 
study by Pan and coworkers, garcinol induced apoptosis at a greater rate than curcumin through 
activation of cascape-3 mediated by release of cytochrome c into the cytoplasm of the cell from 
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mitochondria. The increase in apoptosis was also accompanied with down-regulation of an anti-
apoptotic protein BCL2 together with significant up-regulation of two pro-apoptotic proteins, 
Bad and Bax  [41]. In another cancer cell study, garcinol also exhibited a higher potency of 
growth inhibition against the colon cancer cells as compared to normal immortalized intestinal 
cell line with an increase in cascape-3 activity, indicative of apoptotic pathway activation  [42].  
Additionally, several in vitro studies on garcinol suggested its promising role as an 
antiangiogenic and anti-metastatic agent [43-45]. Garcinol studies in pancreatic cancer cell lines 
conducted in our laboratory have demonstrated down-regulation of several markers of 
angiogenesis and metastasis namely MMP9, IL8, PGE2 and VEGF with garcinol treatment [45]. 
At the present time, garcinol has not been reported to show any toxic effects and was proven by 
previously conducted study as safe to be given up to 0.05% in diet orally [38]. In the discovery 
of new anticancer agents, post-treatment gene expression is one of the tools often used to screen 
the potential of candidate compounds in halting cancer progression. In this study, we 
investigated the effect of garcinol alone and in combination with gemcitabine for potential 
therapeutic effect in pancreatic cancer mouse model. 
1.4 Quantitative Real-Time PCR-Based Analysis of Gene Expression 
A gene that encodes a protein is determined to be expressed in a cell or group of cells 
when its transcribed messenger RNA (mRNA) or the resulting protein product is detected. Most 
commonly, gene expression is being measured for comparative purposes to compare the mRNA 
levels of one or several genes in cells from different sources. These comparisons include studies 
on cancer versus normal cells, cells from an organ in genetically modified organism versus 
normal organism and also intervention studies to test a new drug or compound.   
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Gene expression can be measured by many techniques. One of the techniques is 
quantitative real-time polymerase chain reaction (qPCR)  which enables the continuous 
monitoring of the amplification process as it occurs and uses fluorescent reporter dyes to merge 
the amplification and detection steps. The assay is based on measuring the increase in fluorescent 
signal, which corresponds to the amount of DNA produced during each PCR cycle.  
A single PCR reaction is characterized by the PCR cycle at which fluorescence first rises 
above threshold background levels called threshold cycle (CT). Hence, higher the messenger 
RNA (mRNA) concentration of a target gene, lower is the CT value. The process of qPCR 
consists of three steps: (1) reverse transcriptase-based conversion of RNA to complimentary 
DNA (cDNA), (2) the amplification of cDNA by PCR (through repeated cycle of denaturation, 
annealing and DNA fragment synthesis), and (3) the detection and quantification of amplified 
products-referred as amplicons [46]. 
Results from a real-time PCR experiment can be calculated either using absolute or 
relative quantification. In absolute quantification using the Standard Curve Method, unknowns 
are being quantitated based on a known quantity in which the concentration of quantified serially 
diluted DNA sample is plotted against each dilution’s CT. The CT value of an unknown can then 
be used to extrapolate a value from the standard curve. In relative quantification, the aim is to 
analyze changes in gene expression in a given sample relative to another reference sample such 
as an untreated control sample. This type of quantification is useful for comparing the level of 
gene expression of a particular gene of interest in response to a treatment. The most common 
method for relative quantitation  is the 2
−ΔΔCT
 method which compares the CT value of one target 
gene to another for example, an internal control (most commonly housekeeping gene such as β-
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actin and GAPDH) in a single sample [47]. In this study, we investigated the effect of garcinol 
on the gene expression of genes known to be up-regulated in pancreatic cancer.   
1.5 Selected Genes of Interest in Pancreatic Cancer Progression 
1.5.1 Matrix metallopeptidase-9 (MMP9) 
MMP9 is a type of  matrix metalloproteinases (MMPs). Also called matrixins, these are 
zinc-dependent enzymes that are involved in the degradation of extracellular matrix components. 
MMPs play a central role in cell proliferation, invasion and metastasis of cancer cells. MMP9 
from the family is constantly up-regulated in many types of cancer including pancreatic cancer. 
1.5.2 Cyclin D1 (CCND1) 
CCND1 a member of the highly conserved cyclin family. Cyclins function as cyclin-
dependent  kinases subunit regulators forming a complex with CDK4 or CDK6, whose activity is 
required for cell cycle G1/S transition. Overexpression of CCND1 increases proliferation by 
accelerating the cell transit through the G1 phase. 
1.5.3 B-cell lymphoma-2 (BCL2) 
BCL2 is an anti-apoptosis protein found mainly at the cytoplasmic face of the 
mitochondrial outer membrane and other membrane such as endoplasmic recticulum membrane 
and the nuclear envelope. BCL2 prevents the initiation of protease cascape leading to apoptosis 
by directly or indirectly blocking the release of cytochrome c from the mitochondria which 
results in the delay of cell death [48]. Its high expression is found in various human tumors [49].  
1.5.4 Notch1 
Notch signaling is involved in the cellular developmental pathway including proliferation and 
apoptosis. Notch genes encode proteins which are activated upon interaction with its family 
ligands. Five ligands that have been found in mammals are Dll-1, Dll-3, Dll-4, Jagged-1 and 
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Jagged-1[50]. On activation, Notch is cleaved and intracellular Notch is released and shifted into 
the nucleus. The intracellular Notch associates transcriptional factors which play role in 
regulating the expression of target genes. Dysfunction of intracellular Notch is associated with 
tumorigenesis through prevention of cell differentiation. Notch1 is one of the four vertebrate 
Notch genes that have been identified: Notch1, Notch2, Notch3 and Notch4. Notch1 has been 
reported to cross-talk with another major cell growth and apoptotic pathway such as nuclear 
factor ĸB (NF- ĸB ) and its high expression has been noted to inhibit apoptosis [51]. 
Hypothesis 
Based on literature and in vitro findings in our laboratory, we hypothesized that 
progression of pancreatic cancer in mouse model would lead to an increase expression of MMP9, 
CCND1, BCL2 and also Notch1. Moreover treatment with dietary garcinol should cause a down-
regulation of the above described genes in order for it to be potentially beneficial. This was 
shown to be true in earlier studies from our lab in pancreatic cancer cell lines. However, the in 
vitro findings need to be validated in an in vivo animal model of pancreatic cancer before 
translating the effects to a clinical level. A good animal model should be in very close 
resemblance to the human condition.  One of the best, well-validated and clinically relevant  
models of PDAC to be used for in vivo studies is the  KrasLSL.
G12D
/+;  p53
R172H
/+; PdxCretg/+ 
or KPC transgenic mouse model. 
1.6 KPC Transgenic Mouse Model of Pancreatic Cancer 
 The KrasLSL.
G12D
/+;  p53
R172H
/+; PdxCretg/+ or KPC transgenic mouse model is 
generated by crossing mice with a conditional activated Kras allele (KrasLSL.
G12D
) to transgenic 
strain that expresses Cre recombinase in pancreatic lineages (PdxCregt) and generating a 
conditionally express mutant allele of the Li-Fraumeni human ortholog,, p53
R172H
. Activation of 
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both the KrasLSL.
G12D
 and the p53
R172H
 alleles occurs in tissue progenitor cells of the developing 
mouse pancreas through interbreeding with PdxCretg transgenic animals. KPC mice developed 
advanced PDAC at an early age and resembled many aspects of pancreatic cancer in human. This 
model developed the full range of PanIN lesion that ultimately progresses to manifest carcinoma 
with hundred percent penetrance. Metastases to the liver and lungs are also observed in majority 
of the KPC mice which is similar to what is commonly observed in humans. Furthermore, the 
KPC model also developed associated comorbidities to the human pancreatic cancer such as 
cachexia, jaundice and ascites [30, 52].  
To verify our in vitro findings, we have conducted an in vivo study which aimed to 
investigate the effects of garcinol in pancreatic cancer mouse model. This thesis focuses on the 
change in gene expression observed due to dietary garcinol treatment. The following specific 
aims were proposed to meet the hypothesis that the effect of garcinol as a therapeutic agent in 
pancreatic cancer will be evident in gene expression differences of selected genes from the 
garcinol treated groups compared to the non-treated group. 
Specific aim I: To investigate the gene expression response of the pancreatic tissue 
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR) 
technique. 
Specific aim II: To examine the extent of gene expression response in the distant 
metastasis site following garcinol treatment of the liver tissue using quantitative real-time 
polymerase chain reaction (qPCR) technique. 
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Chapter 2 
Methodology 
 
2.1 Animals 
Forty-two male, KPC (KrasLSL.
G12D
/+;  p53
R172H
/+; PdxCretg/+) transgenic mice aged 
between 6-8 weeks old, obtained from Van Andel Institute (Grand Rapids, MI) were used in this 
study.  Thirty-two of them developed pancreatic cancer by KPC mutation and ten mice with non-
mutated KPC from the same litter served as control.  
2.2 Housing and husbandry 
All animals were housed in individual cage at Wayne State University Division of 
Laboratory Animal Resources (DLAR) facility under standard conditions as approved by the 
Wayne State University Animal Investigation Committee (AIC). All of them were kept in the 
same room with alternating 12 hours light alternating with 12 hours darkness under normal 
humidity and at room temperature. Cage bedding, diets and water were replaced weekly and their 
health were monitored regularly. 
2.3 Experimental protocol 
Upon arrival at the facility, all animals were allowed to acclimatize for one week prior to 
start of the experiment. Following acclimatization period, animals were randomly distributed 
into 4 and 2 experimental groups respectively and were subjected to different diet-treatment 
combination as shown in Figure 3.  The KPC groups, each had similar number of animal (n=8) 
included the control, isocaloric diet-non treated group (KC), Garcinol diet-non treated  group 
(KGr), isocaloric diet-gemcitabine treated group (KGm) and garcinol diet-gemcitabine treated 
group (KGG). The non-KPC groups received no chemotherapy drug  treatment, also had equal 
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number of animal in each group (n=5) with one group was fed with isocaloric diet (CC) and the 
other was fed with garcinol diet (CGr).  
2.4 Experimental diets 
Three groups (KGr, KGG,CGr) were given special diet containing 0.05% Garcinol while 
3 other groups (KC,KGm,CC) received standard purified diet that is isocaloric to the Garcinol 
diet. Garcinol for this study was purchased from Enzo Life Sciences (Plymouth Meeting, PA). 
Both the garcinol diet and the standard diet were formulated and produced by Dyets Inc. 
(Bethlehem, PA). Composition of both diets is shown in Table 1.  
2.5 Experimental procedures 
Experimental procedures carried out for this study as summarized in Table 2 are based on 
the overall project to explore the anti-cancer effects of Garcinol in pancreatic cancer mouse 
model. My report will describe only a portion of the main study, investigating gene expression. 
All mice were provided with their respective diets for 6 weeks and had free access to 
water. Body weight, diet and water intake were recorded twice weekly throughout the study 
duration. Chemotherapy injections from 100mg/5ml Gemcitabine stock were delivered to KGm 
and KGG groups (5ul/g body weight) once-weekly (Week 1-5) while groups with no 
chemotherapy treatment were given placebo injections of saline (0.85% NaCl). Urine was 
collected once a week on weeks 2, 4 and 6 for urinary metabolomic profiling. To confirm the 
presence of pancreatic cancer and for tumor progression monitoring purpose, ultrasound was 
done on week 3 and 6, while MRI was done in week 1 and 5. Upon completion of the experiment 
at Week 6, each animal was anesthetized with the combination of 80 mg/ml Ketamine and 
20mg/ml Xylazine (5ul/g body weight) and euthanized by exsanguination and major organs 
removal prior to blood and tissue collection. Pancreatic and liver tissues were flash-frozen in 
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liquid nitrogen then stored at -80ºC until ready to be used for gene expression analysis (by qPCR 
and miRNA microarray) and histological analysis. 
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Fig. 3 Study design 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
Control groups 
CC: Control mouse, standard purified diet. 
CGr: Control mouse, 0.05% garcinol diet. 
 
 
 
KPC Garcinol Study 
n=42 
Experimental group 
KPC mice 
(KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ ) 
n=32 
Control KPC  group (KC) 
Standard diet/Saline 
n=8 
Garcinol group (KGr) 
Garcinol diet/Saline 
n=8 
Gemcitabine group (KGm) 
Standard diet/Gemcitabine 
n=8 
Gemcitabine Garcinol group 
(KGG) 
Garcinol diet/Gemcitabine 
n=8 
Control group 
Control mice 
(Littermates without mutation) 
n=10 
Control group (CC) 
Standard diet/Saline 
 n=5 
Control Garcinol group (CG) 
Garcinol diet/Saline 
n=5 
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Table 1: Experimental Diets Composition 
 
 
 
 
 
 
 
 
0.05% Garcinol  added Diet Regular Isocaloric Diet 
Ingredient kcal/g grams/ 
kg 
kcal/kg Ingredient kcal/g grams/ 
kg 
kcal/kg 
Casein 3.58 200 716 Casein, High 
Nitrogen 
3.58 200 716 
L-Cystein 4 3 12 L-Cystein 4 3 12 
Sucrose 4 100 400 Sucrose 4 100 400 
Cornstarch 3.6 396.986 1429.1496 Cornstarch 3.6 397.486 1430.9496 
Dyetrose 3.8 132 501.6 Dyetrose 3.8 132 501.6 
Soybean Oil 9 70 630 Soybean Oil 9 70 630 
t-Butyl 
hydroquinone 
0 0.014 0 t-Butyl 
hydroquinone 
0 0.014 0 
Cellulose 0 50 0 Cellulose 0 50 0 
Mineral Mix 
#210025 
0.88 35 30.8 Mineral Mix 
#210025 
0.88 35 30.8 
Vitamin Mix 
#310025 
3.87 10 38.7 Vitamin Mix 
#310025 
3.87 10 38.7 
Choline 
Bitartrate 
0 2.5 0 Choline 
Bitartrate 
0 2.5 0 
Garcinol 0 0.5 0     
  1000.00 3758.2496   1000.00 3760.0496 
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Procedures Frequency of Measurement 
Body weight, diet intake, water intake  
Gemcitabine/saline injection 
MRI 
Ultrasound 
Urine collection 
Blood and tissue collection  
Twice weekly (Week 1-6) 
Once weekly (Week 1-5) 
Week 1, 5 
Week 3, 6 
Once weekly (Week 2,4,6) 
End of study (Week 6) 
 
Table 2: Study timeline based on the overall study 
 
2.6 RNA Extraction   
Four pancreatic samples and five liver samples from each group were taken as 
representative in the  gene expression analysis. Total RNA extraction was performed with a 
commercial kit (RNeasy Mini Kit, Qiagen Valencia, CA, USA) according to the manufacturer’s 
instructions.  First, an approximate weight of 30mg of frozen liver and pancreatic tissues were 
excised and  placed  into 700 uL QIAzol Lysis Reagent in a suitable vessel for disruption and 
homogenization using tissue homogenizer until sample was uniformly homogenous. Tube 
containing homogenate was then placed at room temperature (15-25˚C) for 5 minutes. 140 uL of 
chloroform was then added and tube was capped securely followed by vigorous shaking for 15 
seconds.  The tube was then placed at room temperature for 3 minutes prior to centrifugation for 
15 minutes at 12,000 rcf at 4˚C. Following centrifugation, the upper aqueous phase was 
transferred to a new collection tube. 525 uL of 100% ethanol was added and mixed  thoroughly 
by pipetting.  Next, 700 uL of sample including any precipitate was pipetted into RNeasy Mini 
spin column in 2 ml collection tube and centrifuged  at 10,000 rpm for 15 seconds. The flow-
through was discarded and the same step was repeated for the remainder of sample. 700 uL of 
Buffer RWT was then added to RNeasy Mini spin column, centrifuged  at 10,000 rpm for 15 
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seconds and flow-through was discarded. 500 uL of Buffer RPE was then pipetted onto RNeasy 
Mini spin column and again and centrifuged  at 10,000 rpm for 15 seconds. The flow-through 
was discarded and another 500 uL of Buffer RPE was added to RNeasy Mini column, 
centrifuged  at 10,000 rpm for 2 minutes.  RNeasy Mini spin column was then places into a new 
2 ml collection tube and centrifuged at full speed for 1 minute. The old collection tube was 
discarded with the flow through.  Finally, the RNeasy Mini spin column was transferred  to a 
new 1.5 ml collection tube, 40uL of RNase-free water was pipetted directly on the RNeasy Mini 
spin column membrane and centrifuged for 1 minute at 10,000 rpm to elute the RNA.  Quantity 
measurement and spectrophotometric quality assessment (A260/280 and A260/230 ratios) of RNA 
were then carried out using the Nanodrop spectrophotometer.  
2.7 cDNA Preparation 
Reverse transcription for liver RNA was performed using High Capacity RNA to cDNA 
Master Mix kit (Applied Biosystems, Carlsbad, CA). 20 uL of RT buffer mix, 2 uL of RT 
enzyme mix, 8 uL of RNA sample (equal concentrations of 1000 ng/ul for all samples) and 10 
uL of nuclease-free water were mixed into 0.2 mL PCR tube and centrifuged for few seconds. 
Prepared samples were then  loaded into Eppendorf mastercycler realplex 4 (Eppendorf, 
Hauppauge, NY) for reverse transcription process with the following temperature setting; 25˚C 
for 5 minutes, 42˚C for 30 minutes, 85˚C for 5 minutes and kept at 4˚C until retrieve for 
immediate use for qRT-PCR analysis or transferred to a -20˚C freezer. 
Reverse transcription for pancreatic RNA was performed using miScript II RT Kit 
(Qiagen GmbH, Hilden, Germany). The reverse transcription master mix consisted of 4 uL 5x 
miScript HiFlex Buffer, 2 uL miScript Nucleics Mix, 2 uL miScript Reverse Transcriptase Mix 
and 4 uL RNase-free water  prepared in 0.2 mL PCR tube, gently mixed and stored on ice. Next, 
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8 uL template RNA (equal concentrations of 1000 ng/ul for all samples) was added to each tube 
containing reverse transcription master mix, gently mixed and briefly centrifuged. All prepared 
tubes were then loaded into Eppendorf mastercycler realplex 4 (Eppendorf, Hauppauge, NY) for 
reverse transcription process, incubated at the following temperatures; 37˚C for 60 minutes, 95˚C 
for 5 minutes and kept at 4˚C until retrieve for immediate use for qRT-PCR analysis or 
transferred to a -20˚C freezer. 
2.8 Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
qPCR was performed as part of  gene expression analysis. Four genes which involved in 
tumor progression were tested in pancreatic samples (CyclinD1, MMP9, BCL2, Notch1) and 
three genes were tested in liver samples (CyclinD1, MMP9, BCL2) . The primer sequence of 
these genes are listed in Table 3.  The final reaction volume of  25 uL consisted of 12.5 uL 
SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), 1 uL of 20 uM reverse 
and forward primer mixture,  9.5 uL nuclease-free water and 2 uL of cDNA (equal 
concentrations of 10ng/ul for all samples). qRT-PCR was carried out on the Eppendorf  
mastercycler  realplex 4 instrument (Eppendorf, Hauppauge, NY) in Mx3000P 96-Well Plates 
(Agilent Technologies) with the following program; initial denaturing: 95˚C for 10 minutes, 45 
repeats of denaturing: 95˚C  (15 seconds) and elongation: 60˚C  (1 minute),  dissociation curve: 
95˚C  for 1 minute, 60˚C   for  30 seconds followed by gradual temperature increase from  60˚C  
to 95˚C   in 20 minutes and finally at 95˚C   for 30 seconds. Each gene was analyzed in triplicate 
with single NTC.  mRNA expression levels in the samples were calculated relative to control, 
isocaloric diet-no chemotherapy group (KC) using the comparative CT method:  ∆∆CT = ∆CT 
sample  -  ∆CT control, fold change = 2-∆∆CT.  β-actin was used to normalized the expression values 
(∆CT). 
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2.9 Data Analysis 
 A fold change cut-off of more than 2 was used in determining any significant change of 
gene expression relative to control. 
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Table 3: Primer sequence of the studied genes 
 
 
 
 
 
 
Primer’s 
Name 
Forward Sequence Reverse Sequence 
 
CyclinD1 
 
 
5′-CCTCCAGAGGGCTGT 
CGGCGCAGTAGCAGA- 3′  
 
 
5′-TCTTACCTCCAGCAT 
CCAGGTGGCCACGAT-3′  
MMP9  
 
 
BCl2 
5′- GCTCCTGGTCTCCTG 
GCTT-3′  
 
5′-CCTGTGGATGACTGA 
GTACC-3′ 
5′-GTCCCACTTGAGGC 
CTTTGA-3′  
 
5′-GAGACAGCCAGGAG 
AAATCA-3′ 
Notch-1  
 
 
β-Actin 
5′-CACTGTGGGCGGGT 
CC-3′  
 
5′-ACCAACTGGGACGA 
CATGGAGAAG-3′ 
5′-GTTGTATTGGTTCGGC 
ACCAT-3′  
 
5′-TACGACCAGAGGCAT 
ACAGGGACT-3′ 
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Chapter 3 
Results 
 
The body weight, diet intake, MRI and histological data from our overall study are 
summarized in Table 4. In this study, we have confirmed the presence of pancreatic tumor in the 
experimental groups by ultrasound, MRI and histology. The 0.05% dosage of garcinol added in 
diet has shown to be well tolerated in this study with 100% survival rate was reported in non-
pancreatic cancer group. The data of the results mentioned above will be presented elsewhere. 
The data on change in gene expression due to garcinol intervention, the focus of my study is 
presented here. 
 
Data Observation 
Body weight No significant difference between experimental 
groups 
Diet intake No significant difference between all groups 
MRI  Reduction in number and tumor size in garcinol 
treated groups (KGr and KGG) 
Histology 
 
 
 
miRNA microarray 
Significant reduction in total PanIN count in 
garcinol treated groups (KGr and KGG) 
Less number of PanIN-3 in garcinol treated 
groups (KGr and KGG) 
miRNA related to pancreatic cancer were 
identified and found to be regulated in favorable 
manner 
 
Table 4: Body weight, diet intake, MRI and histological data from the overall study  
 
Specific aim I: To investigate the gene expression response of the pancreatic tissue 
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR) 
technique. 
27 
 
3.1 Gene Expression Analysis of Pancreatic Tissues 
KPC (KrasLSL.
G12D
/+; p53
R172H
/+; PdxCretg/+) transgenic mouse develop tumor in the 
pancreas. Data from experimental group (KC, KGr, KGm and KGG) are presented. Gene 
expression levels are presented relative to the non-treated pancreatic cancer group (KC). 
Cyclin D1 (CCND1) 
As can be seen from Figure 4, the relative pancreatic mRNA expression of CCND1 for 
all three treatments significantly decreased compared to the non-treated cancer group with 
garcinol and garcinol-gemcitabine combination exhibiting more profound reduction. Garcinol 
significantly reduced CCND1 expression to much lower level compared to gemcitabine. 
Likewise, garcinol-gemcitabine combination also significantly lowered CCND1 expression  than 
gemcitabine alone. 
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Fig. 4 Relative pancreatic mRNA expression of CCND1. The expression is presented as fold 
change with respect to KC.
 a
 is significantly different from 
b
 and 
c
. 
b 
is significantly different from 
c
. 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.  
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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Matrix metallopeptidase-9 (MMP9) 
Figure 5 shows the relative pancreatic mRNA expression of MMP9. Treatment with 
garcinol, gemcitabine and garcinol-gemcitabine combination significantly decreased the mRNA 
level of MMP9 compared to the non-treated group. The down-regulation was most significantly 
pronounced with garcinol-gemcitabine combination. Garcinol significantly reduced MMP9 
expression at much lower level compared to gemcitabine and also garcinol-gemcitabine 
combination too had significantly decreased MMP9 expression more compared to gemcitabine. 
Moreover, this combination decreased the expression of MMP9 more than garcinol alone at a 
significant level. 
Notch-1  
All three treatments with garcinol, gemcitabine and garcinol-gemcitabine had 
significantly down-regulated Notch1 compared to the non-treated cancer group (Figure 6). 
Garcinol lowered the Notch1 expression most significantly among the three. Garcinol 
significantly reduced Notch1 expression at much lower level compared to gemcitabine. The 
combination of garcinol-gemcitabine had significantly decreased Notch1 expression more than 
gemcitabine and garcinol treatment alone. 
B-cell lymphoma-2 (BCL2) 
The relative pancreatic mRNA expression of BCL2 is presented in Figure 7. It can be 
seen that garcinol slightly decreased the expression of BCL2. However this down-regulation was 
not significant. Gemcitabine and garcinol-gemcitabine combination increased BCL2 expression 
level compared to both no treatment and garcinol also at a non-significant level. 
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Fig. 5 Relative pancreatic mRNA expression of MMP9. The expression is presented as fold 
change with respect to KC. 
a
 is significantly different from 
b
 and 
c
. 
b 
is significantly different 
from 
c
. 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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Fig. 6 Relative pancreatic mRNA expression of NOTCH1. The expression is presented as fold 
change with respect to KC. 
a
 is significantly different from 
b
 and 
c
. 
b 
is significantly different 
from 
c
. 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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Fig. 7 Relative pancreatic mRNA expression of BCL2. The expression is presented as fold 
change with respect to KC. There is no significant difference in mRNA expression levels of each 
group in comparison with KC. 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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Specific aim II: To examine the extent of gene expression response in the distant 
metastasis site following garcinol treatment of the liver tissue using quantitative real-time 
polymerase chain reaction (qPCR) technique. 
3.2 Gene Expression Analysis of Liver Tissues 
Liver is one of the first organs for the primary tumor in the pancreas to be metastasized. 
Data from experimental group (KC, KGr, KGm, KGG) is presented. Gene expression levels are 
presented relative to the non-treated pancreatic cancer group (KC). 
Cyclin D1 (CCND1) 
Figure 8 shows the relative liver mRNA expression of CCND1. In the experimental 
groups, the expression of CCND1 was significantly decreased with garcinol treatmeant, 
gemcitabine treatment and garcinol-gemcitabine treatment combination with the later (garcinol-
gemcitabine) showing the most down-regulation of CCND1 expression compared to no 
treatment. It can be seen that garcinol-gemcitabine combination decreased CCND1 expression 
more than garcinol and gemcitabine treatment alone but the decrease in expression was not 
significant, as compared to either treatment alone.  
Matrix metallopeptidase-9 (MMP9) 
As shown in Figure 9, the relative liver mRNA expression of MMP9 in the experimental 
groups was significantly decreased with garcinol treatmeant, and garcinol-gemcitabine treatment 
combination. However, down-regulation of MMP9 following Gemcitabine treatment was at a 
non-significant level. Garcinol and garcinol-gemcitabine combination decreased the MMP9 
expression at a lower, non-significant levels compared to gemcitabine.  
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Fig. 8 Relative liver mRNA expression of CCND1. The expression is presented as fold change 
with respect to KC. 
a
 is significantly different from 
b
.  
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
  
 
 
 
 
 
 
 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
KC KGr KGm KGG 
R
e
la
ti
ve
 E
xp
re
ss
io
n
 (F
o
ld
 C
h
an
ge
) a 
b 
b 
b 
35 
 
 
 
Fig. 9 Relative liver mRNA expression of MMP9. The expression is presented as fold change 
with respect to KC. 
a
 is significantly different from 
b
. There is no significant difference in mRNA 
expression levels of KGm in comparison with KC, KGr and KGG. 
 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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B-cell lymphoma-2 (BCL2) 
 It can be seen from Figure 10 that both gemcitabine and garcinol-gemcitabine 
combination treatment of the experimental group significantly decreased the expression of BCL2 
with the combined treatment being more pronounced. Garcinol also exhibited a reduction in 
BCL2 level but the decrease was not significant.  
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Fig. 10 Relative liver mRNA expression of BCL2. The expression is presented as fold change 
with respect to KC. 
a
 is significantly different from 
b
. There is no significant difference in mRNA 
expression level of KGr in comparison with KC. 
 
 
 
Experimental groups 
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment. 
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment. 
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment. 
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment. 
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Chapter 4 
Discussion 
 
Pancreatic cancer is currently ranked as the fourth leading cause of cancer-related deaths 
in The United States with high mortality rate majorly contributed by late diagnosis, early 
metastasis of tumors and poor response to treatments, making it so important to develop new 
approaches in order to improve the prognosis of this lethal disease. Most chemotherapeutic 
treatments for pancreatic cancer are at a disadvantage of having adverse toxic reactions. Thus, 
development of effective preventative and/or therapeutic treatments for pancreatic cancer that are 
relatively nontoxic from single agents or combination with an established drug treatment is 
warranted. This thesis reports the potential anticancer effect of garcinol, a compound extracted 
from Garcinia indica fruit rind which may have promise for treating this lethal malignancy. 
Using KPC mouse-model for pancreatic cancer, this study has evaluated the mRNA expression 
response of selected genes in pancreatic tumorigenesis following garcinol treatment alone, 
gemcitabine treatment alone and also garcinol-gemcitabine combination relative to non-treated 
group using quantitative real-time polymerase chain reaction (qPCR) technique.  
In this study, we report the potential of garcinol for its future use as a chemotherapeutic 
agent for pancreatic cancer. Figure 11 summarizes the in vivo anticancer activity of garcinol in 
pancreatic cancer as observed from this study. We report herein that garcinol caused a significant 
down-regulation of three out of four genes tested which could possibly halt the tumor 
progression via inhibition of proliferation, angiogenesis and metastasis and via increment in 
apoptosis activity.  Interestingly, this study also report the similar observation with garcinol-
gemcitabine treatment combination. These results show that garcinol may have potential in 
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pancreatic cancer chemoprevention not only limited by its use as a single treatment agent but 
may provide additive effect when use in combination with gemcitabine. 
 
 
 
 
 
 
 
 
 
 
Fig. 11 In vivo anticancer activity of Garcinol in pancreatic cancer 
 
 
The cyclin D1 (CCND1) is frequently over expressed in pancreatic ductal 
adenocarcinoma. Cyclins function as cyclin-dependent kinases subunit regulators forming a 
complex with CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. 
Overexpression of CCND1 increases proliferation by accelerating the cell transit through the G1 
phase. Moreover, there is also present evidence that CCND1 plays a role in tumor cell migration 
[53]. In this study, we observed that both garcinol and garcinol-gemcitabine treatment 
significantly reduced the expression of CCND1 thus, suggesting the anti-proliferative property of 
garcinol by its ability to arrest cell cycle.   
↓ CCND1 
Anti-proliferative 
 
↓ MMP9 
Anti-angiogenesis 
Anti-metastasis 
 
 
Garcinol & 
Garcinol + gemcitabine 
↓ Notch1 
Proapoptotic 
Anti-proliferative 
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Matrix metalloproteinases (MMPs) also called matrixins are zinc-dependent enzymes 
known to be the agent to degrade extracellular matrix components. Its role in tumor metastasis, 
invasion, angiogenesis and metastasis is well established. This current study demonstrates that 
garcinol down-regulated the level of pancreatic MMP9 relative to untreated group significantly. 
Moreover, it was also observed that garcinol and gemcitabine displayed synergistic effect in 
inhibiting MMP9 when compared to single treatment of garcinol or gemcitabine. Similar 
observation was obtained for liver samples. This finding accords the earlier in vitro observation 
which showed that garcinol causes inhibition of MMP9 activity [45]. These results provide 
further support for the hypothesis that garcinol is capable of arresting metastasis and cell 
invasion by interrupting MMP9 activity.  
Apoptosis induction is one of the most important aspects in evaluating anticancer 
properties of treated animals. BCL2 is as an anti-apoptotic protein known to be overexpressed in 
pancreatic cancer [49] and prevents the initiation of protease caspase leading to apoptosis by 
directly or indirectly blocking the release of cytochrome c from the mitochondria which results 
in the delay of cell death [48]. It was observed from this study that garcinol slightly down-
regulated the expression of BCL2 in both pancreatic and liver samples at a non-significant level. 
Contrary to expectations, garcinol-gemcitabine combination increased pancreatic BCL2 
expression compared to both no treatment and garcinol also at a non-significant level.  The 
opposite observation was obtained in liver samples in which combination of garcinol-
gemcitabine treatment showed an additive effect resulted in a significant reduction of BCL2 
expression.  It is well accepted that p53 mutation leads to activation of BCL2 in pancreatic 
cancer. Thus, we speculate that this difference in observation is due to the animal model used in 
this research. The KPC mouse model selected for this study has conditional mutations in K-ras 
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and p53 genes.The activation of the mutant p53 in this model occurs exclusively in tissue 
progenitor cells of the developing mouse pancreas which leads to the activation of BCL2 in the 
pancreas.  This high activation of BCL2 in the pancreas might provide the possible explanation 
on why was the significant down-regulation of BCL2 with garcinol-gemcitabine treatment 
observed only in liver sample but not in pancreatic sample. 
The Notch signaling pathway is a fundamental signaling system used by neighboring 
cells to communicate with each other in order to assume their proper developmental role. Notch 
signaling is involved in the cellular developmental pathway including proliferation and 
apoptosis. Notch1 has been reported to cross-talk with another major cell growth and apoptotic 
pathway such as nuclear factor ĸB (NF- ĸB ) and its high expression has been noted to inhibit 
apoptosis [51]. It has also been reported in the study by Wang et al., that down-regulation of 
Notch1 inhibited cell growth and induced apoptosis in pancreatic cancer cells [51]. However, 
very little was found in the literature on the question of whether garcinol is capable of down-
regulating Notch1 in pancreatic cancer. Our observations highlight the therapeutic benefit of 
garcinol by a significant down-regulation of Notch1 level compared to the non-treated group. It 
was observed that the combination of garcinol-gemcitabine effectively down-regulated Notch1 
more than gemcitabine and garcinol treatment alone. From these earlier findings it is likely that 
the potential inhibition of cell growth and apoptosis induction by garcinol treatment in pancreatic 
cancer is achieved through down-regulation of Notch1.  
Moreover, the findings on garcinol and its synergistic effect with gemcitabine in the 
down-regulation of several genes as discussed above are also supported by the data from other 
experiments conducted in our overall study, which will be reported elsewhere. Our MRI data 
showed that garcinol had effectively reduced the number and size of tumor and a greater effect 
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was observed in the garcinol-gemcitabine treated group. From our histological observation, we 
found that garcinol alone and garcinol-gemcitabine combination significantly reduced the 
number of all PanINs (PanIN-1, PanIN-2 and PanIN-3). It was also observed that PanIN-3 lesion 
count in garcinol treated groups (KGr and KGG) was lowered compared to the untreated group. 
These histological findings are indicative of garcinol’s potential in prolonging the onset of 
adenocarcinoma and in halting its progression.  
In conclusion, despite the need for further investigation, garcinol exhibits anti-
poliferative, proapoptotic, anti-angiogenesis and anti-metastatic properties which is evident by 
the significant down-regulation of CCND1, MMP9 and Notch1. The findings in this study add to 
a growing body of literature on anticancer effects of garcinol and contributes to additional 
evidence that suggests its chemotherapeutic effect on pancreatic cancer  previously shown in in 
vitro setting is extended into animal model. Interestingly, we also showed that the promising 
pancreatic cancer chemotherapeutic effect of garcinol   is not only limited by its use as a single 
treatment agent.  Garcinol may also provide additive effect when use in combination with 
gemcitabine suggesting its potential use as a natural adjuvant in pancreatic cancer treatment 
regimens. Further investigation and experimentation on garcinol’s anticancer effect in pancreatic 
cancer animal models investigating many other mechanistic targets is strongly recommended.  
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 Pancreatic cancer is currently ranked as the fourth leading cause of cancer-related deaths 
in The United States making it so important to develop new approaches in order to improve the 
prognosis of this lethal disease. Chemotherapy drugs as treatment for pancreatic cancer are 
known to have adverse toxic reactions. Thus, development of treatments for pancreatic cancer 
that are relatively nontoxic is warranted. This thesis reports the potential anticancer effect of 
garcinol, a compound extracted from Garcinia indica fruit rind which may have promise for 
treating this lethal malignancy. Using KPC mouse-model for pancreatic cancer, this study has 
evaluated the mRNA expression response of selected genes in pancreatic tumorigenesis 
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR) 
technique. We concluded from this study that garcinol and its combination with gemcitabine 
exhibit  anti-poliferative, proapoptotic, anti-angiogenesis and anti-metastatic properties which is 
evident by the significant down-regulation of CCND1, MMP9 and Notch1 in both pancreatic and 
liver tissues. The findings in this study contribute to additional evidence that suggests its 
chemotherapeutic effect on pancreatic cancer previously shown in in vitro setting is extended 
into animal model. 
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